Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy
Abstract The WHO estimates that more than 185 million people are infected with hepatitis C virus (HCV) worldwide. The aim of the study is to assess the incremental cost-effectiveness ratio (ICER) of the use of daclatasvir (DCV) + sofosbuvir (SOF) + ribavirin (RBV) for 12 and 16 weeks vs SOF + RBV fo...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Restelli, Umberto [verfasserIn] |
|---|
| Format: |
Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Springer-Verlag Berlin Heidelberg 2016 |
|---|
| Übergeordnetes Werk: |
Enthalten in: The European journal of health economics - Springer Berlin Heidelberg, 2001, 19(2016), 1 vom: 22. Dez., Seite 37-44 |
|---|---|
| Übergeordnetes Werk: |
volume:19 ; year:2016 ; number:1 ; day:22 ; month:12 ; pages:37-44 |
| Links: |
|---|
| DOI / URN: |
10.1007/s10198-016-0865-3 |
|---|
| Katalog-ID: |
OLC2052297839 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2052297839 | ||
| 003 | DE-627 | ||
| 005 | 20230502175527.0 | ||
| 007 | tu | ||
| 008 | 200820s2016 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10198-016-0865-3 |2 doi | |
| 035 | |a (DE-627)OLC2052297839 | ||
| 035 | |a (DE-He213)s10198-016-0865-3-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 330 |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.05$jGesundheitsökonomie |2 bkl | ||
| 084 | |a 44.10$jGesundheitswesen: Allgemeines |2 bkl | ||
| 100 | 1 | |a Restelli, Umberto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Springer-Verlag Berlin Heidelberg 2016 | ||
| 520 | |a Abstract The WHO estimates that more than 185 million people are infected with hepatitis C virus (HCV) worldwide. The aim of the study is to assess the incremental cost-effectiveness ratio (ICER) of the use of daclatasvir (DCV) + sofosbuvir (SOF) + ribavirin (RBV) for 12 and 16 weeks vs SOF + RBV for 16 and 24 weeks for the treatment of genotype 3 HCV infected cirrhotic patients from the Italian National Health Service (NHS) perspective. A published cohort-based Markov model was used to perform the analysis estimating the lifetime direct medical costs associated with the management of the pathology and the quality adjusted life years gained by patients. Deterministic and probabilistic sensitivity analyses were performed to test the robustness of the results. SOF + RBV for 16 weeks was excluded from the analysis due to the significant lower effectiveness, compared with SOF + RBV for 24 weeks (51% vs 79%). DCV + SOF + RBV would increase QALYs and costs in all the comparisons: the ICERs obtained comparing DCV + SOF + RBV for 12 and 16 weeks with SOF + RBV for 24 weeks (reference scenario) are 38,572 €/QALY and 16,436 €/QALY, respectively, both below the 40,000 €/QALY threshold identified by the Italian Health Economics Association. Sensitivity analyses confirmed the robustness of the results. The use of DCV + SOF + RBV is likely to be cost-effective compared with SOF + RBV (for 24 weeks) for the treatment of cirrhotic patients infected with genotype 3 HCV considering a threshold value of 40,000 €/QALY. | ||
| 650 | 4 | |a Hepatitis C virus | |
| 650 | 4 | |a Cost-effectiveness analysis | |
| 650 | 4 | |a Daclatasvir | |
| 650 | 4 | |a Italy | |
| 700 | 1 | |a Alberti, Alfredo |4 aut | |
| 700 | 1 | |a Lazzarin, Adriano |4 aut | |
| 700 | 1 | |a Bonfanti, Marzia |4 aut | |
| 700 | 1 | |a Nappi, Carmela |4 aut | |
| 700 | 1 | |a Croce, Davide |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The European journal of health economics |d Springer Berlin Heidelberg, 2001 |g 19(2016), 1 vom: 22. Dez., Seite 37-44 |w (DE-627)328188557 |w (DE-600)2045253-6 |w (DE-576)09442246X |x 1618-7598 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2016 |g number:1 |g day:22 |g month:12 |g pages:37-44 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s10198-016-0865-3 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-WIW | ||
| 912 | |a GBV_ILN_26 | ||
| 912 | |a GBV_ILN_267 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_2026 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4277 | ||
| 912 | |a GBV_ILN_4310 | ||
| 912 | |a GBV_ILN_4314 | ||
| 936 | b | k | |a 44.05$jGesundheitsökonomie |q VZ |0 106409611 |0 (DE-625)106409611 |
| 936 | b | k | |a 44.10$jGesundheitswesen: Allgemeines |q VZ |0 106409530 |0 (DE-625)106409530 |
| 951 | |a AR | ||
| 952 | |d 19 |j 2016 |e 1 |b 22 |c 12 |h 37-44 | ||
| author_variant |
u r ur a a aa a l al m b mb c n cn d c dc |
|---|---|
| matchkey_str |
article:16187598:2016----::otfetvnsaayiotesodcaavroobvriaii1wesn1wessoobvriaii1wesn2wesoteramnocrhtc |
| hierarchy_sort_str |
2016 |
| bklnumber |
44.05$jGesundheitsökonomie 44.10$jGesundheitswesen: Allgemeines |
| publishDate |
2016 |
| allfields |
10.1007/s10198-016-0865-3 doi (DE-627)OLC2052297839 (DE-He213)s10198-016-0865-3-p DE-627 ger DE-627 rakwb eng 330 610 VZ 610 VZ 44.05$jGesundheitsökonomie bkl 44.10$jGesundheitswesen: Allgemeines bkl Restelli, Umberto verfasserin aut Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy 2016 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier © Springer-Verlag Berlin Heidelberg 2016 Abstract The WHO estimates that more than 185 million people are infected with hepatitis C virus (HCV) worldwide. The aim of the study is to assess the incremental cost-effectiveness ratio (ICER) of the use of daclatasvir (DCV) + sofosbuvir (SOF) + ribavirin (RBV) for 12 and 16 weeks vs SOF + RBV for 16 and 24 weeks for the treatment of genotype 3 HCV infected cirrhotic patients from the Italian National Health Service (NHS) perspective. A published cohort-based Markov model was used to perform the analysis estimating the lifetime direct medical costs associated with the management of the pathology and the quality adjusted life years gained by patients. Deterministic and probabilistic sensitivity analyses were performed to test the robustness of the results. SOF + RBV for 16 weeks was excluded from the analysis due to the significant lower effectiveness, compared with SOF + RBV for 24 weeks (51% vs 79%). DCV + SOF + RBV would increase QALYs and costs in all the comparisons: the ICERs obtained comparing DCV + SOF + RBV for 12 and 16 weeks with SOF + RBV for 24 weeks (reference scenario) are 38,572 €/QALY and 16,436 €/QALY, respectively, both below the 40,000 €/QALY threshold identified by the Italian Health Economics Association. Sensitivity analyses confirmed the robustness of the results. The use of DCV + SOF + RBV is likely to be cost-effective compared with SOF + RBV (for 24 weeks) for the treatment of cirrhotic patients infected with genotype 3 HCV considering a threshold value of 40,000 €/QALY. Hepatitis C virus Cost-effectiveness analysis Daclatasvir Italy Alberti, Alfredo aut Lazzarin, Adriano aut Bonfanti, Marzia aut Nappi, Carmela aut Croce, Davide aut Enthalten in The European journal of health economics Springer Berlin Heidelberg, 2001 19(2016), 1 vom: 22. Dez., Seite 37-44 (DE-627)328188557 (DE-600)2045253-6 (DE-576)09442246X 1618-7598 nnns volume:19 year:2016 number:1 day:22 month:12 pages:37-44 https://doi.org/10.1007/s10198-016-0865-3 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-WIW GBV_ILN_26 GBV_ILN_267 GBV_ILN_2018 GBV_ILN_2026 GBV_ILN_4219 GBV_ILN_4277 GBV_ILN_4310 GBV_ILN_4314 44.05$jGesundheitsökonomie VZ 106409611 (DE-625)106409611 44.10$jGesundheitswesen: Allgemeines VZ 106409530 (DE-625)106409530 AR 19 2016 1 22 12 37-44 |
| spelling |
10.1007/s10198-016-0865-3 doi (DE-627)OLC2052297839 (DE-He213)s10198-016-0865-3-p DE-627 ger DE-627 rakwb eng 330 610 VZ 610 VZ 44.05$jGesundheitsökonomie bkl 44.10$jGesundheitswesen: Allgemeines bkl Restelli, Umberto verfasserin aut Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy 2016 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier © Springer-Verlag Berlin Heidelberg 2016 Abstract The WHO estimates that more than 185 million people are infected with hepatitis C virus (HCV) worldwide. The aim of the study is to assess the incremental cost-effectiveness ratio (ICER) of the use of daclatasvir (DCV) + sofosbuvir (SOF) + ribavirin (RBV) for 12 and 16 weeks vs SOF + RBV for 16 and 24 weeks for the treatment of genotype 3 HCV infected cirrhotic patients from the Italian National Health Service (NHS) perspective. A published cohort-based Markov model was used to perform the analysis estimating the lifetime direct medical costs associated with the management of the pathology and the quality adjusted life years gained by patients. Deterministic and probabilistic sensitivity analyses were performed to test the robustness of the results. SOF + RBV for 16 weeks was excluded from the analysis due to the significant lower effectiveness, compared with SOF + RBV for 24 weeks (51% vs 79%). DCV + SOF + RBV would increase QALYs and costs in all the comparisons: the ICERs obtained comparing DCV + SOF + RBV for 12 and 16 weeks with SOF + RBV for 24 weeks (reference scenario) are 38,572 €/QALY and 16,436 €/QALY, respectively, both below the 40,000 €/QALY threshold identified by the Italian Health Economics Association. Sensitivity analyses confirmed the robustness of the results. The use of DCV + SOF + RBV is likely to be cost-effective compared with SOF + RBV (for 24 weeks) for the treatment of cirrhotic patients infected with genotype 3 HCV considering a threshold value of 40,000 €/QALY. Hepatitis C virus Cost-effectiveness analysis Daclatasvir Italy Alberti, Alfredo aut Lazzarin, Adriano aut Bonfanti, Marzia aut Nappi, Carmela aut Croce, Davide aut Enthalten in The European journal of health economics Springer Berlin Heidelberg, 2001 19(2016), 1 vom: 22. Dez., Seite 37-44 (DE-627)328188557 (DE-600)2045253-6 (DE-576)09442246X 1618-7598 nnns volume:19 year:2016 number:1 day:22 month:12 pages:37-44 https://doi.org/10.1007/s10198-016-0865-3 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-WIW GBV_ILN_26 GBV_ILN_267 GBV_ILN_2018 GBV_ILN_2026 GBV_ILN_4219 GBV_ILN_4277 GBV_ILN_4310 GBV_ILN_4314 44.05$jGesundheitsökonomie VZ 106409611 (DE-625)106409611 44.10$jGesundheitswesen: Allgemeines VZ 106409530 (DE-625)106409530 AR 19 2016 1 22 12 37-44 |
| allfields_unstemmed |
10.1007/s10198-016-0865-3 doi (DE-627)OLC2052297839 (DE-He213)s10198-016-0865-3-p DE-627 ger DE-627 rakwb eng 330 610 VZ 610 VZ 44.05$jGesundheitsökonomie bkl 44.10$jGesundheitswesen: Allgemeines bkl Restelli, Umberto verfasserin aut Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy 2016 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier © Springer-Verlag Berlin Heidelberg 2016 Abstract The WHO estimates that more than 185 million people are infected with hepatitis C virus (HCV) worldwide. The aim of the study is to assess the incremental cost-effectiveness ratio (ICER) of the use of daclatasvir (DCV) + sofosbuvir (SOF) + ribavirin (RBV) for 12 and 16 weeks vs SOF + RBV for 16 and 24 weeks for the treatment of genotype 3 HCV infected cirrhotic patients from the Italian National Health Service (NHS) perspective. A published cohort-based Markov model was used to perform the analysis estimating the lifetime direct medical costs associated with the management of the pathology and the quality adjusted life years gained by patients. Deterministic and probabilistic sensitivity analyses were performed to test the robustness of the results. SOF + RBV for 16 weeks was excluded from the analysis due to the significant lower effectiveness, compared with SOF + RBV for 24 weeks (51% vs 79%). DCV + SOF + RBV would increase QALYs and costs in all the comparisons: the ICERs obtained comparing DCV + SOF + RBV for 12 and 16 weeks with SOF + RBV for 24 weeks (reference scenario) are 38,572 €/QALY and 16,436 €/QALY, respectively, both below the 40,000 €/QALY threshold identified by the Italian Health Economics Association. Sensitivity analyses confirmed the robustness of the results. The use of DCV + SOF + RBV is likely to be cost-effective compared with SOF + RBV (for 24 weeks) for the treatment of cirrhotic patients infected with genotype 3 HCV considering a threshold value of 40,000 €/QALY. Hepatitis C virus Cost-effectiveness analysis Daclatasvir Italy Alberti, Alfredo aut Lazzarin, Adriano aut Bonfanti, Marzia aut Nappi, Carmela aut Croce, Davide aut Enthalten in The European journal of health economics Springer Berlin Heidelberg, 2001 19(2016), 1 vom: 22. Dez., Seite 37-44 (DE-627)328188557 (DE-600)2045253-6 (DE-576)09442246X 1618-7598 nnns volume:19 year:2016 number:1 day:22 month:12 pages:37-44 https://doi.org/10.1007/s10198-016-0865-3 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-WIW GBV_ILN_26 GBV_ILN_267 GBV_ILN_2018 GBV_ILN_2026 GBV_ILN_4219 GBV_ILN_4277 GBV_ILN_4310 GBV_ILN_4314 44.05$jGesundheitsökonomie VZ 106409611 (DE-625)106409611 44.10$jGesundheitswesen: Allgemeines VZ 106409530 (DE-625)106409530 AR 19 2016 1 22 12 37-44 |
| allfieldsGer |
10.1007/s10198-016-0865-3 doi (DE-627)OLC2052297839 (DE-He213)s10198-016-0865-3-p DE-627 ger DE-627 rakwb eng 330 610 VZ 610 VZ 44.05$jGesundheitsökonomie bkl 44.10$jGesundheitswesen: Allgemeines bkl Restelli, Umberto verfasserin aut Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy 2016 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier © Springer-Verlag Berlin Heidelberg 2016 Abstract The WHO estimates that more than 185 million people are infected with hepatitis C virus (HCV) worldwide. The aim of the study is to assess the incremental cost-effectiveness ratio (ICER) of the use of daclatasvir (DCV) + sofosbuvir (SOF) + ribavirin (RBV) for 12 and 16 weeks vs SOF + RBV for 16 and 24 weeks for the treatment of genotype 3 HCV infected cirrhotic patients from the Italian National Health Service (NHS) perspective. A published cohort-based Markov model was used to perform the analysis estimating the lifetime direct medical costs associated with the management of the pathology and the quality adjusted life years gained by patients. Deterministic and probabilistic sensitivity analyses were performed to test the robustness of the results. SOF + RBV for 16 weeks was excluded from the analysis due to the significant lower effectiveness, compared with SOF + RBV for 24 weeks (51% vs 79%). DCV + SOF + RBV would increase QALYs and costs in all the comparisons: the ICERs obtained comparing DCV + SOF + RBV for 12 and 16 weeks with SOF + RBV for 24 weeks (reference scenario) are 38,572 €/QALY and 16,436 €/QALY, respectively, both below the 40,000 €/QALY threshold identified by the Italian Health Economics Association. Sensitivity analyses confirmed the robustness of the results. The use of DCV + SOF + RBV is likely to be cost-effective compared with SOF + RBV (for 24 weeks) for the treatment of cirrhotic patients infected with genotype 3 HCV considering a threshold value of 40,000 €/QALY. Hepatitis C virus Cost-effectiveness analysis Daclatasvir Italy Alberti, Alfredo aut Lazzarin, Adriano aut Bonfanti, Marzia aut Nappi, Carmela aut Croce, Davide aut Enthalten in The European journal of health economics Springer Berlin Heidelberg, 2001 19(2016), 1 vom: 22. Dez., Seite 37-44 (DE-627)328188557 (DE-600)2045253-6 (DE-576)09442246X 1618-7598 nnns volume:19 year:2016 number:1 day:22 month:12 pages:37-44 https://doi.org/10.1007/s10198-016-0865-3 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-WIW GBV_ILN_26 GBV_ILN_267 GBV_ILN_2018 GBV_ILN_2026 GBV_ILN_4219 GBV_ILN_4277 GBV_ILN_4310 GBV_ILN_4314 44.05$jGesundheitsökonomie VZ 106409611 (DE-625)106409611 44.10$jGesundheitswesen: Allgemeines VZ 106409530 (DE-625)106409530 AR 19 2016 1 22 12 37-44 |
| allfieldsSound |
10.1007/s10198-016-0865-3 doi (DE-627)OLC2052297839 (DE-He213)s10198-016-0865-3-p DE-627 ger DE-627 rakwb eng 330 610 VZ 610 VZ 44.05$jGesundheitsökonomie bkl 44.10$jGesundheitswesen: Allgemeines bkl Restelli, Umberto verfasserin aut Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy 2016 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier © Springer-Verlag Berlin Heidelberg 2016 Abstract The WHO estimates that more than 185 million people are infected with hepatitis C virus (HCV) worldwide. The aim of the study is to assess the incremental cost-effectiveness ratio (ICER) of the use of daclatasvir (DCV) + sofosbuvir (SOF) + ribavirin (RBV) for 12 and 16 weeks vs SOF + RBV for 16 and 24 weeks for the treatment of genotype 3 HCV infected cirrhotic patients from the Italian National Health Service (NHS) perspective. A published cohort-based Markov model was used to perform the analysis estimating the lifetime direct medical costs associated with the management of the pathology and the quality adjusted life years gained by patients. Deterministic and probabilistic sensitivity analyses were performed to test the robustness of the results. SOF + RBV for 16 weeks was excluded from the analysis due to the significant lower effectiveness, compared with SOF + RBV for 24 weeks (51% vs 79%). DCV + SOF + RBV would increase QALYs and costs in all the comparisons: the ICERs obtained comparing DCV + SOF + RBV for 12 and 16 weeks with SOF + RBV for 24 weeks (reference scenario) are 38,572 €/QALY and 16,436 €/QALY, respectively, both below the 40,000 €/QALY threshold identified by the Italian Health Economics Association. Sensitivity analyses confirmed the robustness of the results. The use of DCV + SOF + RBV is likely to be cost-effective compared with SOF + RBV (for 24 weeks) for the treatment of cirrhotic patients infected with genotype 3 HCV considering a threshold value of 40,000 €/QALY. Hepatitis C virus Cost-effectiveness analysis Daclatasvir Italy Alberti, Alfredo aut Lazzarin, Adriano aut Bonfanti, Marzia aut Nappi, Carmela aut Croce, Davide aut Enthalten in The European journal of health economics Springer Berlin Heidelberg, 2001 19(2016), 1 vom: 22. Dez., Seite 37-44 (DE-627)328188557 (DE-600)2045253-6 (DE-576)09442246X 1618-7598 nnns volume:19 year:2016 number:1 day:22 month:12 pages:37-44 https://doi.org/10.1007/s10198-016-0865-3 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-WIW GBV_ILN_26 GBV_ILN_267 GBV_ILN_2018 GBV_ILN_2026 GBV_ILN_4219 GBV_ILN_4277 GBV_ILN_4310 GBV_ILN_4314 44.05$jGesundheitsökonomie VZ 106409611 (DE-625)106409611 44.10$jGesundheitswesen: Allgemeines VZ 106409530 (DE-625)106409530 AR 19 2016 1 22 12 37-44 |
| language |
English |
| source |
Enthalten in The European journal of health economics 19(2016), 1 vom: 22. Dez., Seite 37-44 volume:19 year:2016 number:1 day:22 month:12 pages:37-44 |
| sourceStr |
Enthalten in The European journal of health economics 19(2016), 1 vom: 22. Dez., Seite 37-44 volume:19 year:2016 number:1 day:22 month:12 pages:37-44 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Hepatitis C virus Cost-effectiveness analysis Daclatasvir Italy |
| dewey-raw |
330 |
| isfreeaccess_bool |
false |
| container_title |
The European journal of health economics |
| authorswithroles_txt_mv |
Restelli, Umberto @@aut@@ Alberti, Alfredo @@aut@@ Lazzarin, Adriano @@aut@@ Bonfanti, Marzia @@aut@@ Nappi, Carmela @@aut@@ Croce, Davide @@aut@@ |
| publishDateDaySort_date |
2016-12-22T00:00:00Z |
| hierarchy_top_id |
328188557 |
| dewey-sort |
3330 |
| id |
OLC2052297839 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">OLC2052297839</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502175527.0</controlfield><controlfield tag="007">tu</controlfield><controlfield tag="008">200820s2016 xx ||||| 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10198-016-0865-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)OLC2052297839</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-He213)s10198-016-0865-3-p</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">330</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.05$jGesundheitsökonomie</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.10$jGesundheitswesen: Allgemeines</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Restelli, Umberto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">ohne Hilfsmittel zu benutzen</subfield><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Band</subfield><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Springer-Verlag Berlin Heidelberg 2016</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract The WHO estimates that more than 185 million people are infected with hepatitis C virus (HCV) worldwide. The aim of the study is to assess the incremental cost-effectiveness ratio (ICER) of the use of daclatasvir (DCV) + sofosbuvir (SOF) + ribavirin (RBV) for 12 and 16 weeks vs SOF + RBV for 16 and 24 weeks for the treatment of genotype 3 HCV infected cirrhotic patients from the Italian National Health Service (NHS) perspective. A published cohort-based Markov model was used to perform the analysis estimating the lifetime direct medical costs associated with the management of the pathology and the quality adjusted life years gained by patients. Deterministic and probabilistic sensitivity analyses were performed to test the robustness of the results. SOF + RBV for 16 weeks was excluded from the analysis due to the significant lower effectiveness, compared with SOF + RBV for 24 weeks (51% vs 79%). DCV + SOF + RBV would increase QALYs and costs in all the comparisons: the ICERs obtained comparing DCV + SOF + RBV for 12 and 16 weeks with SOF + RBV for 24 weeks (reference scenario) are 38,572 €/QALY and 16,436 €/QALY, respectively, both below the 40,000 €/QALY threshold identified by the Italian Health Economics Association. Sensitivity analyses confirmed the robustness of the results. The use of DCV + SOF + RBV is likely to be cost-effective compared with SOF + RBV (for 24 weeks) for the treatment of cirrhotic patients infected with genotype 3 HCV considering a threshold value of 40,000 €/QALY.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hepatitis C virus</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cost-effectiveness analysis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Daclatasvir</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Italy</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alberti, Alfredo</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lazzarin, Adriano</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bonfanti, Marzia</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nappi, Carmela</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Croce, Davide</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">The European journal of health economics</subfield><subfield code="d">Springer Berlin Heidelberg, 2001</subfield><subfield code="g">19(2016), 1 vom: 22. Dez., Seite 37-44</subfield><subfield code="w">(DE-627)328188557</subfield><subfield code="w">(DE-600)2045253-6</subfield><subfield code="w">(DE-576)09442246X</subfield><subfield code="x">1618-7598</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:1</subfield><subfield code="g">day:22</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:37-44</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">https://doi.org/10.1007/s10198-016-0865-3</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_OLC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-WIW</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_26</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2018</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4219</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4277</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4310</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4314</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.05$jGesundheitsökonomie</subfield><subfield code="q">VZ</subfield><subfield code="0">106409611</subfield><subfield code="0">(DE-625)106409611</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.10$jGesundheitswesen: Allgemeines</subfield><subfield code="q">VZ</subfield><subfield code="0">106409530</subfield><subfield code="0">(DE-625)106409530</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2016</subfield><subfield code="e">1</subfield><subfield code="b">22</subfield><subfield code="c">12</subfield><subfield code="h">37-44</subfield></datafield></record></collection>
|
| author |
Restelli, Umberto |
| spellingShingle |
Restelli, Umberto ddc 330 ddc 610 bkl 44.05$jGesundheitsökonomie bkl 44.10$jGesundheitswesen: Allgemeines misc Hepatitis C virus misc Cost-effectiveness analysis misc Daclatasvir misc Italy Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy |
| authorStr |
Restelli, Umberto |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)328188557 |
| format |
Article |
| dewey-ones |
330 - Economics 610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut |
| collection |
OLC |
| remote_str |
false |
| illustrated |
Not Illustrated |
| issn |
1618-7598 |
| topic_title |
330 610 VZ 610 VZ 44.05$jGesundheitsökonomie bkl 44.10$jGesundheitswesen: Allgemeines bkl Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy Hepatitis C virus Cost-effectiveness analysis Daclatasvir Italy |
| topic |
ddc 330 ddc 610 bkl 44.05$jGesundheitsökonomie bkl 44.10$jGesundheitswesen: Allgemeines misc Hepatitis C virus misc Cost-effectiveness analysis misc Daclatasvir misc Italy |
| topic_unstemmed |
ddc 330 ddc 610 bkl 44.05$jGesundheitsökonomie bkl 44.10$jGesundheitswesen: Allgemeines misc Hepatitis C virus misc Cost-effectiveness analysis misc Daclatasvir misc Italy |
| topic_browse |
ddc 330 ddc 610 bkl 44.05$jGesundheitsökonomie bkl 44.10$jGesundheitswesen: Allgemeines misc Hepatitis C virus misc Cost-effectiveness analysis misc Daclatasvir misc Italy |
| format_facet |
Aufsätze Gedruckte Aufsätze |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
nc |
| hierarchy_parent_title |
The European journal of health economics |
| hierarchy_parent_id |
328188557 |
| dewey-tens |
330 - Economics 610 - Medicine & health |
| hierarchy_top_title |
The European journal of health economics |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)328188557 (DE-600)2045253-6 (DE-576)09442246X |
| title |
Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy |
| ctrlnum |
(DE-627)OLC2052297839 (DE-He213)s10198-016-0865-3-p |
| title_full |
Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy |
| author_sort |
Restelli, Umberto |
| journal |
The European journal of health economics |
| journalStr |
The European journal of health economics |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
300 - Social sciences 600 - Technology |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
txt |
| container_start_page |
37 |
| author_browse |
Restelli, Umberto Alberti, Alfredo Lazzarin, Adriano Bonfanti, Marzia Nappi, Carmela Croce, Davide |
| container_volume |
19 |
| class |
330 610 VZ 610 VZ 44.05$jGesundheitsökonomie bkl 44.10$jGesundheitswesen: Allgemeines bkl |
| format_se |
Aufsätze |
| author-letter |
Restelli, Umberto |
| doi_str_mv |
10.1007/s10198-016-0865-3 |
| normlink |
106409611 106409530 |
| normlink_prefix_str_mv |
106409611 (DE-625)106409611 106409530 (DE-625)106409530 |
| dewey-full |
330 610 |
| title_sort |
cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis c virus genotype 3 in italy |
| title_auth |
Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy |
| abstract |
Abstract The WHO estimates that more than 185 million people are infected with hepatitis C virus (HCV) worldwide. The aim of the study is to assess the incremental cost-effectiveness ratio (ICER) of the use of daclatasvir (DCV) + sofosbuvir (SOF) + ribavirin (RBV) for 12 and 16 weeks vs SOF + RBV for 16 and 24 weeks for the treatment of genotype 3 HCV infected cirrhotic patients from the Italian National Health Service (NHS) perspective. A published cohort-based Markov model was used to perform the analysis estimating the lifetime direct medical costs associated with the management of the pathology and the quality adjusted life years gained by patients. Deterministic and probabilistic sensitivity analyses were performed to test the robustness of the results. SOF + RBV for 16 weeks was excluded from the analysis due to the significant lower effectiveness, compared with SOF + RBV for 24 weeks (51% vs 79%). DCV + SOF + RBV would increase QALYs and costs in all the comparisons: the ICERs obtained comparing DCV + SOF + RBV for 12 and 16 weeks with SOF + RBV for 24 weeks (reference scenario) are 38,572 €/QALY and 16,436 €/QALY, respectively, both below the 40,000 €/QALY threshold identified by the Italian Health Economics Association. Sensitivity analyses confirmed the robustness of the results. The use of DCV + SOF + RBV is likely to be cost-effective compared with SOF + RBV (for 24 weeks) for the treatment of cirrhotic patients infected with genotype 3 HCV considering a threshold value of 40,000 €/QALY. © Springer-Verlag Berlin Heidelberg 2016 |
| abstractGer |
Abstract The WHO estimates that more than 185 million people are infected with hepatitis C virus (HCV) worldwide. The aim of the study is to assess the incremental cost-effectiveness ratio (ICER) of the use of daclatasvir (DCV) + sofosbuvir (SOF) + ribavirin (RBV) for 12 and 16 weeks vs SOF + RBV for 16 and 24 weeks for the treatment of genotype 3 HCV infected cirrhotic patients from the Italian National Health Service (NHS) perspective. A published cohort-based Markov model was used to perform the analysis estimating the lifetime direct medical costs associated with the management of the pathology and the quality adjusted life years gained by patients. Deterministic and probabilistic sensitivity analyses were performed to test the robustness of the results. SOF + RBV for 16 weeks was excluded from the analysis due to the significant lower effectiveness, compared with SOF + RBV for 24 weeks (51% vs 79%). DCV + SOF + RBV would increase QALYs and costs in all the comparisons: the ICERs obtained comparing DCV + SOF + RBV for 12 and 16 weeks with SOF + RBV for 24 weeks (reference scenario) are 38,572 €/QALY and 16,436 €/QALY, respectively, both below the 40,000 €/QALY threshold identified by the Italian Health Economics Association. Sensitivity analyses confirmed the robustness of the results. The use of DCV + SOF + RBV is likely to be cost-effective compared with SOF + RBV (for 24 weeks) for the treatment of cirrhotic patients infected with genotype 3 HCV considering a threshold value of 40,000 €/QALY. © Springer-Verlag Berlin Heidelberg 2016 |
| abstract_unstemmed |
Abstract The WHO estimates that more than 185 million people are infected with hepatitis C virus (HCV) worldwide. The aim of the study is to assess the incremental cost-effectiveness ratio (ICER) of the use of daclatasvir (DCV) + sofosbuvir (SOF) + ribavirin (RBV) for 12 and 16 weeks vs SOF + RBV for 16 and 24 weeks for the treatment of genotype 3 HCV infected cirrhotic patients from the Italian National Health Service (NHS) perspective. A published cohort-based Markov model was used to perform the analysis estimating the lifetime direct medical costs associated with the management of the pathology and the quality adjusted life years gained by patients. Deterministic and probabilistic sensitivity analyses were performed to test the robustness of the results. SOF + RBV for 16 weeks was excluded from the analysis due to the significant lower effectiveness, compared with SOF + RBV for 24 weeks (51% vs 79%). DCV + SOF + RBV would increase QALYs and costs in all the comparisons: the ICERs obtained comparing DCV + SOF + RBV for 12 and 16 weeks with SOF + RBV for 24 weeks (reference scenario) are 38,572 €/QALY and 16,436 €/QALY, respectively, both below the 40,000 €/QALY threshold identified by the Italian Health Economics Association. Sensitivity analyses confirmed the robustness of the results. The use of DCV + SOF + RBV is likely to be cost-effective compared with SOF + RBV (for 24 weeks) for the treatment of cirrhotic patients infected with genotype 3 HCV considering a threshold value of 40,000 €/QALY. © Springer-Verlag Berlin Heidelberg 2016 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-WIW GBV_ILN_26 GBV_ILN_267 GBV_ILN_2018 GBV_ILN_2026 GBV_ILN_4219 GBV_ILN_4277 GBV_ILN_4310 GBV_ILN_4314 |
| container_issue |
1 |
| title_short |
Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy |
| url |
https://doi.org/10.1007/s10198-016-0865-3 |
| remote_bool |
false |
| author2 |
Alberti, Alfredo Lazzarin, Adriano Bonfanti, Marzia Nappi, Carmela Croce, Davide |
| author2Str |
Alberti, Alfredo Lazzarin, Adriano Bonfanti, Marzia Nappi, Carmela Croce, Davide |
| ppnlink |
328188557 |
| mediatype_str_mv |
n |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s10198-016-0865-3 |
| up_date |
2024-07-03T14:33:47.991Z |
| _version_ |
1803568784857890816 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">OLC2052297839</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502175527.0</controlfield><controlfield tag="007">tu</controlfield><controlfield tag="008">200820s2016 xx ||||| 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10198-016-0865-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)OLC2052297839</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-He213)s10198-016-0865-3-p</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">330</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.05$jGesundheitsökonomie</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.10$jGesundheitswesen: Allgemeines</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Restelli, Umberto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">ohne Hilfsmittel zu benutzen</subfield><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Band</subfield><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Springer-Verlag Berlin Heidelberg 2016</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract The WHO estimates that more than 185 million people are infected with hepatitis C virus (HCV) worldwide. The aim of the study is to assess the incremental cost-effectiveness ratio (ICER) of the use of daclatasvir (DCV) + sofosbuvir (SOF) + ribavirin (RBV) for 12 and 16 weeks vs SOF + RBV for 16 and 24 weeks for the treatment of genotype 3 HCV infected cirrhotic patients from the Italian National Health Service (NHS) perspective. A published cohort-based Markov model was used to perform the analysis estimating the lifetime direct medical costs associated with the management of the pathology and the quality adjusted life years gained by patients. Deterministic and probabilistic sensitivity analyses were performed to test the robustness of the results. SOF + RBV for 16 weeks was excluded from the analysis due to the significant lower effectiveness, compared with SOF + RBV for 24 weeks (51% vs 79%). DCV + SOF + RBV would increase QALYs and costs in all the comparisons: the ICERs obtained comparing DCV + SOF + RBV for 12 and 16 weeks with SOF + RBV for 24 weeks (reference scenario) are 38,572 €/QALY and 16,436 €/QALY, respectively, both below the 40,000 €/QALY threshold identified by the Italian Health Economics Association. Sensitivity analyses confirmed the robustness of the results. The use of DCV + SOF + RBV is likely to be cost-effective compared with SOF + RBV (for 24 weeks) for the treatment of cirrhotic patients infected with genotype 3 HCV considering a threshold value of 40,000 €/QALY.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hepatitis C virus</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cost-effectiveness analysis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Daclatasvir</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Italy</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alberti, Alfredo</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lazzarin, Adriano</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bonfanti, Marzia</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nappi, Carmela</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Croce, Davide</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">The European journal of health economics</subfield><subfield code="d">Springer Berlin Heidelberg, 2001</subfield><subfield code="g">19(2016), 1 vom: 22. Dez., Seite 37-44</subfield><subfield code="w">(DE-627)328188557</subfield><subfield code="w">(DE-600)2045253-6</subfield><subfield code="w">(DE-576)09442246X</subfield><subfield code="x">1618-7598</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:1</subfield><subfield code="g">day:22</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:37-44</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">https://doi.org/10.1007/s10198-016-0865-3</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_OLC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-WIW</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_26</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2018</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4219</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4277</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4310</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4314</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.05$jGesundheitsökonomie</subfield><subfield code="q">VZ</subfield><subfield code="0">106409611</subfield><subfield code="0">(DE-625)106409611</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.10$jGesundheitswesen: Allgemeines</subfield><subfield code="q">VZ</subfield><subfield code="0">106409530</subfield><subfield code="0">(DE-625)106409530</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2016</subfield><subfield code="e">1</subfield><subfield code="b">22</subfield><subfield code="c">12</subfield><subfield code="h">37-44</subfield></datafield></record></collection>
|
| score |
7.4022894 |